Prediction: 2 Stocks That Will Be Worth More Than NuScale Power 10 Years From Now
The Motley Fool· 2025-06-17 00:50
Core Viewpoint - Nuclear power is gaining attention, with NuScale Power's market cap at $11 billion and a stock increase of 360% over the past year, but it is a pre-revenue company with significant risks [1][11][12] Group 1: NuScale Power - NuScale Power has a market cap exceeding $10 billion but generates zero revenue currently, relying on contracts for future projects [11][12] - The company is not expected to generate revenue until 2030, and even then, it may be negligible due to unproven technology and previous project cancellations [12][13] - The stock is considered risky, with expectations of declining value over the next decade [13] Group 2: Rocket Lab - Rocket Lab has a similar market cap to NuScale Power but generates revenue, distinguishing it as a more viable investment [2][5] - The company has successfully completed 59 launches and has 31 planned missions, positioning itself as a competitor to SpaceX [3][5] - Rocket Lab's revenue stands at $466 million, with potential for significant growth through the introduction of the Neutron rocket and a product backlog exceeding $1 billion [5] Group 3: Rivian Automotive - Rivian Automotive, currently down 92% from its all-time highs, aims to recover with new product launches, including the R2 mid-size SUV priced at $45,000 [6][8] - The company has struggled with stagnating deliveries, currently below 50,000, and negative free cash flow of $1.86 billion over the past year [8][9] - With a scaled-up operation, Rivian could increase annual revenue from $5 billion to between $15 billion and $20 billion, potentially achieving a market cap larger than NuScale Power in 10 years [9]
Take-Two Stock Is Crushing the Nasdaq in 2025. Is It a Buy?
The Motley Fool· 2025-06-17 00:45
Core Viewpoint - Take-Two Interactive has shown strong stock performance, up 27% year to date, significantly outperforming the Nasdaq Composite, which is up only 0.59% [1] - The company reported impressive financial results for fiscal 2025, with a focus on upcoming game releases, including GTA VI, to drive future growth [1][4] Recent Business Performance and Outlook - Take-Two's non-GAAP revenue grew 6% year over year in fiscal 2025, with a notable 17% increase in the most recent quarter [4] - Recurrent consumer spending, which includes player spending on virtual currency and content, accounted for 80% of bookings in fiscal 2025 [5] - For fiscal 2026, management projects bookings to increase by 6% to approximately $6 billion [6] - The highly anticipated GTA VI is set to release on May 26, 2026, with Wall Street estimating bookings could reach $9 billion in fiscal 2027 [7] Historical Growth and Future Projections - Over the past decade, Take-Two has achieved an annualized revenue growth rate of 18%, despite recent profit and cash flow impacts from the acquisition of Zynga [9] - The company aims to expand its game portfolio and increase recurrent consumer spending to enhance margins and revenue [10] - Management expressed confidence in achieving operating margins in the low to mid-20% range, similar to levels during the pandemic [11] Valuation and Investment Considerations - The stock is currently trading at high price-to-sales and forward price-to-earnings multiples, reflecting market expectations for growth [13] - A discounted cash flow model suggests an intrinsic value of $236, assuming double-digit revenue growth to $18 billion by 2035 with a 25% operating margin [15] - To justify a fair value of $300, more aggressive growth projections would be necessary, such as achieving a 30% operating margin or growing revenue to $25 billion [16] - While the stock has potential for modest returns, current valuations suggest it may not significantly outperform the broader market [17]
Lightspeed Commerce Announces Settlement Agreement for Quebec Class Action
Prnewswire· 2025-06-17 00:34
Core Viewpoint - Lightspeed Commerce Inc. has reached an agreement in principle to fully resolve proposed class action proceedings in Quebec, following the dismissal of a similar U.S. securities class action against the company, which found the allegations to lack legal basis [1][2][3]. Group 1: Settlement Details - The settlement amount is approximately $8.09 million, equivalent to C$11 million, based on an exchange rate of 0.7354 [3][4]. - The settlement is subject to approval by the Superior Court of Quebec and aims to settle all claims against the company and other defendants, with no admission of liability or wrongdoing [2][3]. Group 2: Company Transformation - The company is undergoing a transformation focused on strategic growth and aims to build a long-term profitable business for customers and shareholders [3]. - The resolution of the class action allows the company to concentrate on markets where it has a competitive advantage and to enhance customer experiences globally [3]. Group 3: Company Overview - Lightspeed operates as a unified omnichannel platform for retail and hospitality businesses in over 100 countries [1][5]. - The company provides a range of services including point of sale, e-commerce, embedded payments, inventory management, and financial services [6].
This Stock Is Up Over 8,700%, and Still Makes Sense to Own Today
The Motley Fool· 2025-06-17 00:32
Company Overview - Realty Income is a real estate investment trust (REIT) that finances, owns, and operates income-producing real estate, primarily focusing on single-unit freestanding commercial properties [4][5] - The company has over 15,600 properties across 91 industries and eight countries, with notable clients including 7-Eleven, Dollar Tree, and FedEx [6] Investment Performance - Realty Income's stock has experienced an impressive return of over 8,700% since its inception, significantly outperforming the stock market's average annual return of around 10% [2][1] - The stock price has grown 1,280%, with dividends accounting for the majority of total returns [7][8] Dividend Characteristics - Realty Income offers a monthly dividend of $0.2690, which annualizes to $3.228, and has a compound annual growth rate (CAGR) of 4.2% [8][14] - The company has declared dividends for 660 consecutive months and has increased its dividend payout for the past 111 quarters [14] Economic Resilience - Realty Income maintains a high occupancy rate of 98.5%, with a historical low of 96.6% recorded in 2010, indicating strong tenant retention [10] - Approximately 91% of the company's rent comes from clients that are resilient to economic downturns, such as grocery stores and drugstores [11][12] Market Potential - The total addressable market (TAM) for Realty Income is estimated to be around $14 trillion, indicating significant growth opportunities in the future [13]
Prediction: This Unstoppable "Magnificent Seven" Member Will Be Wall Street's First $5 Trillion Stock, and Billionaire Bill Ackman Just Bought the Dip
The Motley Fool· 2025-06-17 00:30
Billionaire hedge fund manager Bill Ackman recently revealed that his firm is building a stake in Amazon stock.While there isn't an official start date marking the artificial intelligence (AI) revolution, I personally like to use Nov. 30, 2022, as my timestamp. This is the day that OpenAI released ChatGPT to the public, virtually changing how businesses and consumers access information at the flip of a switch.Back then, Amazon (AMZN 1.81%) sported a market capitalization of $835 billion. Today, the company' ...
3 Reasons to Buy Target Stock Like There's No Tomorrow
The Motley Fool· 2025-06-17 00:23
Target (TGT 2.03%) is one of the leading retailers in the United States, often looked at as a more upscale Walmart. While that's a pretty good description of the business, it isn't the best comparison today because Walmart's business is doing fairly well while Target's stores aren't. But for contrarian investors, there are still some strong reasons to buy Target stock while it looks like it's on sale.1. Target has a historically high yieldFor many investors, the big reason to like Target today is its 4.5% d ...
Pinterest and Instacart Form Deal Enabling Shoppable Ads
PYMNTS.com· 2025-06-17 00:02
Group 1 - Pinterest and Instacart have formed a retail media collaboration that allows Pinterest ads to become directly shoppable via Instacart, enabling users to complete purchases quickly and have items delivered in as little as 30 minutes [1][2] - The collaboration will initially allow select brands on Pinterest to target Instacart's first-party audience segments based on real-world retail purchase behavior, with plans to introduce closed-loop measurement to link Pinterest ads to actual sales on the Instacart Marketplace [3] - This partnership is part of Instacart's broader advertising ecosystem, which includes over 220 grocery eCommerce sites and various off-platform collaborations [4] Group 2 - The collaboration aims to enhance the shopping experience by transforming user inspiration on Pinterest into actual purchases, leveraging Instacart's retail media data to target high-intent users effectively [5] - Instacart has previously partnered with YouTube to make video ads shoppable, indicating a trend towards integrating shoppable features across various platforms to facilitate same-day delivery for consumers [6] - Pinterest has reported a significant increase in outbound clicks to advertisers, having more than doubled these clicks year over year for three consecutive quarters, highlighting the platform's growing effectiveness in driving sales [6]
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against 3D Systems Corporation (DDD)
GlobeNewswire News Room· 2025-06-17 00:00
Core Viewpoint - A securities class action lawsuit has been filed against 3D Systems Corporation for allegedly making false and misleading statements regarding its financial performance and business conditions during the class period from August 13, 2024, to May 12, 2025 [1][2]. Group 1: Allegations and Financial Performance - The lawsuit claims that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [2]. - The updated milestone criteria in the United Partnership are alleged to negatively impact the Company's Regenerative Medicine Program revenue [2]. - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, and sales revenue of $111 million, which is a -3.4% year-over-year decline [3]. - For the full year 2024, the Company reported sales of $440.1 million, a decrease of 10% compared to the prior year, attributed to lower hardware systems sales due to macroeconomic factors [3]. - A $9 million revenue reduction in Q4 was reported due to a change in accounting estimates for the Regenerative Medicine program [3]. - Following the financial results announcement, 3D Systems' stock price fell by $0.57 per share, or 20.96%, closing at $2.15 per share on March 27, 2025 [3]. Group 2: Legal Proceedings - Investors who purchased shares of 3D Systems are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on August 12, 2025 [4]. - The lead plaintiff will act on behalf of other class members in directing the litigation [4].
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. (TEM)
GlobeNewswire News Room· 2025-06-17 00:00
Core Viewpoint - A securities class action lawsuit has been filed against Tempus AI, Inc. for alleged misrepresentations and failures to disclose critical information regarding its financial practices and operations during the specified class period [1][2]. Allegations of Misconduct - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to artificially inflate revenue [2] - The business model of Tempus-acquired Ambry is alleged to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement, raising further concerns about the company's financial integrity [2] - These issues collectively indicate weaknesses in Tempus' core operations and revenue prospects [2]. Impact of External Reports - A report from Spruce Point Capital Management highlighted numerous red flags regarding Tempus' management and financial reporting, including a history of executives cashing out before public shareholders incur losses [3] - The report also criticized the overstated AI capabilities of Tempus and pointed out aggressive accounting practices [3] - Concerns were raised about the AstraZeneca and Pathos AI deal, which warranted further scrutiny [3] - The company's recent financial guidance was seen as indicative of weaknesses in its core operations [3]. Stock Price Reaction - Following the release of the report and the ensuing allegations, Tempus' stock price dropped by $12.67 per share, or 19.23%, from $65.87 on May 27, 2025, to $53.20 on May 28, 2025 [4].
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
Prnewswire· 2025-06-16 23:48
Core Viewpoint - CSL has received FDA approval for ANDEMBRY®, a novel treatment for hereditary angioedema (HAE), marking a significant advancement in the management of this rare genetic disorder [1][3][11] Group 1: Product Overview - ANDEMBRY is the first monoclonal antibody developed entirely by CSL, targeting factor XIIa to prevent HAE attacks in patients aged 12 and older [1][3][11] - The treatment offers once-monthly subcutaneous self-injection, providing a convenient administration method [1][3] - ANDEMBRY has shown a median reduction of more than 99% in HAE attacks compared to placebo, with a least squares mean reduction of 89.2% [6][7] Group 2: Clinical Trial Data - The approval is based on data from the pivotal Phase 3 VANGUARD trial, which demonstrated the efficacy and safety of ANDEMBRY [3][12] - In the pivotal trial, 62% of patients treated with ANDEMBRY remained attack-free throughout the treatment period [7] - The most common adverse reactions reported were nasopharyngitis and abdominal pain, with injection-site reactions occurring in 14% of patients [4][7] Group 3: Market Impact and Availability - ANDEMBRY's approval expands CSL's HAE franchise and reinforces the company's commitment to innovation in the HAE community [6][8] - The product is set to launch commercially immediately, with availability expected before the end of June 2025 [9] - ANDEMBRY has also received approvals in multiple regions, including Australia, the UK, the EU, Japan, Switzerland, and the UAE [8]